US Patent 9212217 Antibody molecules to dengue virus and uses thereof
Patent 9212217 was granted and assigned to Visterra Inc. on December, 2015 by the United States Patent and Trademark Office.
All edits
Edits on 7 Aug, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
0
Edits on 12 Mar, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 3 Dec, 2023
Golden AI
Edits made to:
Article (+276 characters)
Article
Patent abstract
Antibody molecules that specifically bind to dengue virus are disclosed. In certain embodiments, the antibody molecule bind to dengue virus serotypes DV-1, DV-2, DV-3, and DV-4. The antibody molecules can be used to treat, prevent, and/or diagnose dengue virus.
Edits on 23 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 20 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 09212217 Antibody molecules to dengue virus and uses thereof US Patent 9212217 Antibody molecules to dengue virus and uses thereof
Infobox
Patent Number
09212217
Patent Number
9212217
Edits on 17 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 4 Jan, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 09212217 Antibody molecules to dengue virus and uses thereof
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
09212217
Date of patent
December 15, 2015
Patent application number
14600306
Date Filed
January 20, 2015
Patent primary examiner
Find more entities like US Patent 9212217 Antibody molecules to dengue virus and uses thereof
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
